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Abstract
Background: Diabetes mellitus (DM) and impaired glucose tolerance (IGT) are risk factors for acute myocardial
infarction (AMI). However, it is unknown whether hyperglycemic state is associated with increased major adverse
cardiovascular events (MACE) after AMI. In this study, we evaluated the relationship between glucometabolic status
and MACE in patients after AMI, and determined the critical level of 2 h post-load plasma glucose that may be
used to predict MACE.
Methods: AMI patients (n = 422) were divided into 4 groups as follows: normal glucose tolerance (NGT) group, IGT
group, newly diagnosed DM (NDM) group, and previously known DM (PDM) group. MACE of the 4 groups were
compared for 2 years from AMI onset.
Results: The NDM group had a significantly higher event rate than the IGT and NGT groups and had a similar
event rate curve to PDM group. The logistic models analyses revealed that 2 h post-load plasma glucose values of
≥160 mg/dL was the only independent predictor of long-term MACE after AMI (p = 0.028, OR: 1.85, 95% CI: 1.07-
3.21). The 2-year cardiac event rate of patients with a 2 h post-load hyperglycemia of ≥160 mg/dL was significantly
higher than that of patients with 2 h post-load glucose of <160 mg/dL (32.2% vs. 19.8%, p < 0.05) and was similar
to that of PDM group (37.4%, p = 0.513).
Conclusions: NDM increases the risk of MACE after AMI as does PDM. Particularly, post-AMI patients with a 2 h
post-load hyperglycemia ≥160 mg/dL may need adjunctive therapy after AMI.
Introduction
It is well known that diabetes mellitus (DM) is an inde-
pendent risk factor for cardiovascular disease (CVD).
The risk of CVD for diabetic patients is two to three
times higher than that of subjects without DM [1-4]. In
addition, several previous studies have shown that post-
load hyperglycemia such as impaired glucose tolerance
(IGT) is a risk factor for CVD [5-7]. In patients with
acute myocardial infarction (AMI), the prevalence of
abnormal glucose tolerance (AGT) using an oral glucose
tolerance test (OGTT) was >70% [8-11]. In the GAMI
(Glucose Abnormalities in Patients with Myocardial
Infarction) study and the report by Tamita et al, AGT
including IGT and newly diagnosed DM (NDM) were
strong predictors of major adverse cardiac events
(MACE) after AMI [12,13].
The risk for poor long-term prognosis after AMI may
be already apparent if patients have post-load hypergly-
cemia even at plasma glucose level well below the dia-
betic threshold. The threshold for definition of DM is
primarily based on a post-load two-hour (2 h) plasma
glucose level in patients with diabetic retinopathy.
Hence, cardiovascular disease has not been considered
as a factor in the classification of glucose tolerance
abnormality.
In the current study, we performed a retrospective
analysis of patients with AMI whose glucose tolerance
were assessed by using a 75 g OGTT, and evaluated the
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long-term MACE. We also determined the critical level
of the 2 h post-load plasma glucose to predict the
occurrence of MACE.
Methods
Study Patients
Between January 2000 and December 2004, a total of
763 patients with first AMI were admitted to the
National Cardiovascular Center (Osaka, Japan). Of the
763 patients admitted, 422 patients who received glu-
cose tolerance tests or were previously known to have
DM were evaluated for cardiac events for two years.
The diagnosis of AMI was based on the presence of
typical chest pain, ST-segment change or new Q-waves
in the 12-lead electrocardiogram, an increase of ≥2-fold
over the upper limit of normal in creatine kinase con-
centration, local asynergy of left ventricular wall on
ultrasound cardiography or left ventriculography, or
occlusion of coronary artery on coronary angiography.
Patients with transient left ventricular ballooning syn-
drome, vasospasm, spontaneous coronary artery dissec-
tion, thromboembolism, catheter related complications,
left main trunk infarction, type 1 diabetes mellitus or
familial hyperlipidemia were excluded from the study.
Classification of abnormal glucose tolerance
Glucose abnormalities of study patients were classified
into 4 groups using a 75 g OGTT according to the criteria
for glucometabolic disturbances established by the World
Health Organization (WHO). This was because we first
started to evaluate abnormal glucose tolerance using a 75
g OGTT in patients after AMI in year 2000 [14,15]. Only
4 Patients with impaired fasting glucose tolerance were
defined as IGT according to Japanese diabetes criteria. A
75 g OGTT was performed in the stable phase of AMI
(median: 9 days from the onset of AMI). Previously
known DM (PDM) patients were defined as those with
clinical history of using oral hypoglycemic agents and/or
insulin and patients with fasting plasma glucose levels
≥126 mg/dL. The other patients were urged to evaluate
t h e i rg l u c o s et o l e r a n c eb ya7 5gO G T T .N D Mw a s
defined as fasting glucose level <126 mg/dL and a 2 h
post-load glucose level ≥200 mg/dL. Normal glucose toler-
ance (NGT) was defined as fasting glucose level <110 mg/
dL and a 2 h post-load glucose level <140 mg/dL. In the
remaining patients, IGT was defined as fasting glucose
level <126 mg/dL and a 2 h post-load glucose level ≥140
mg/dL or with fasting glucose level of 110-125 mg/dL and
a 2 h post-load glucose level <140 mg/dL.
Data Collection
All patients who survived the acute phase (≤30 days)
were followed-up at the outpatient clinic and their data
for MACE were collected. Three patients with PDM
died during the acute phase. In this study, a total of 422
patients were followed-up for two years. Patients’ out-
comes were assessed on the basis of MACE, which
included death from cardiovascular causes, nonfatal
AMI, hospitalization for heart failure and revasculariza-
tion for restenosis and de novo lesions. Revasculariza-
tion was performed after obtaining ischemic evidence by
several modalities.
To determine the predictors of long-term MACE, the
baseline clinical characteristics of the patients including
laboratory data, characteristics of AMI, and medications
(Table 1) were evaluated using hospital records under
the auspices of the institutional cardiovascular outcomes
monitoring program.
Statistical Analyses
SPSS Software version 17.0 (Chicago, USA) was used for
all statistical analyses. Continuous variables were
expressed as mean ± standard deviation (SD). Statistical
significance was evaluated using unpaired Student’s
t test for comparisons between two means, and a chi-
square test for categorical data. Event-free survival
curves were constructed using the Kaplan-Meier survival
methods and were compared with log-rank statistics.
Survival time was defined as the intervals between the
onset of AMI and the time of MACE. Receiver-operat-
ing characteristic (ROC) analysis was performed to
define sensitivity and specificity of 2 h post-load plasma
glucose. In addition, ROC analysis was used as an
exploratory evaluation of the best cut-off point of 2 h
post-load plasma glucose to predict MACE after AMI in
non-PDM patients and positive and negative predictive
values were derived using this cut-off value. Logistic
regression analysis was used to identify predictors of
cardiac events. A p value of < 0.05 was considered sta-
tistically significant.
Results
Clinical backgrounds and prevalence of glucose
abnormalities
Figure 1 shows a flow diagram for the enrollment of
patients into this study. Of the total 763 patients, we
excluded a total of 247 patients; 48 patients for etiology
of AMI, 11 patients for clinical history of type1 DM and
familial hyperlipidemia, and 188 patients who did not
consent to have the 75 g OGTT. Three patients with
PDM died during the acute phase (≤30 days) after AMI.
In all, 422 patients completed two years of follow-up
from onset; 91 patients dropped out during the study
and did not complete the two years of follow up. The
clinical characteristics of the patients who completed
t h es t u d ya r es h o w ni nT a b l e1 .T h eP D Mg r o u p
had a higher mean age, and a higher prevalence of
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NGT IGT NDM PDM
(n = 106) (n = 140) (n = 68) (n = 108)
Basic characteristics
Male, n (%) 77 (72.6) 108 (77.1) 56 (82.4) 86 (79.6)
Age, year 64 ± 11 66 ± 10 63 ± 11 68 ± 9.* ***
Body-mass index, kg/m
2 23.4 ± 3.0 23.5 ± 2.6 24.5 ± 2.7* ** 24.2 ± 2.9* **
Family history of IHD, n (%) 30 (28.3) 45(32.1) 19 (27.9) 26 (24.1)
History of smoking, n (%) 80 (75.5) 99(70.7) 56 (82.4) 79 (73.1)
Clinical history, n (%)
Hypertension, n (%) 66 (62.3) 82 (58.6) 41 (60.3) 63 (58.3)
Hyperlipidemia, n (%) 62 (58.5) 84 (60.0) 44 (64.7) 62 (57.4)
Heart failure, n (%) 2 (1.9) 2 (1.4) 0 (0.0) 2 (1.9)
Cerebrovascular disease, n (%) 4 (3.8) 12(8.6) 2 (2.9) 13 (12.0)*
Chronic renal failure, n (%) 2 (1.9) 9 (6.4) 1(1.5) 9 (8.3)
ASO, n (%) 5(4.7) 6 (4.3) 4 (5.9) 17 (15.7)* **
Chronic obstructive pulmonary disease, n (%) 2 (1.9) 5 (3.6) 1 (1.5) 1 (0.9)
Malignancy, n (%) 4 (3.8) 11 (7.9) 3 (4.4) 3 (2.8)
Previous procedures (PTCA/CABG), n (%) 3 (2.8) 7 (5.0) 6 (8.8) 8 (7.4)
Laboratory data at the time of admission
Fasting blood sugar, mg/dL 90 ± 7 94 ± 9.* 99 ± 11* **
Blood sugar after 2 h, mg/dL 115 ± 18 165 ± 20* 237 ± 30* **
HbA1c, % 5.3 ± 0.3 5.4 ± 0.5* 5.7 ± 0.4* ** 8.1 ± 1.5* ** ***
Total Cholesterol, mg/dL 194 ± 39 193 ± 37 199 ± 33 199 ± 42
Triglyceride, mg/dL 107 ± 85 102 ± 56 123 ± 74** 122 ± 87**
LDL-Cholesterol, mg/dL 130 ± 37 130 ± 32 129 ± 33 130 ± 36
HDL-Cholesterol, mg/dL 44 ± 11 43 ± 12 45 ± 20 45 ± 12
Serum creatinine, mg/dL 0.8 ± 0.2 0.8 ± 0.3 0.8 ± 0.2 0.9 ± 0.3
Urea acid, mg/dL 5.3 ± 1.5 5.5 ± 1.6 5.6 ± 1.3 5.2 ± 1.8
Characteristics of acute myocardial infarction
Systolic blood pressure on admission, mmHg 135 ± 25 139 ± 23 139 ± 24 136 ± 24
Heart rate on admission, bpm/m 72 ± 17 75 ± 16 76 ± 18 77 ± 19
Killip class≧Ⅱ, n (%) 9 (8.5) 5 (3.6) 4 (5.9) 15 (13.9)**
Anterior MI, n (%) 45 (42.5) 77 (55.0) 28 (41.2) 50 (46.3)
Multi-vessel disease, n (%) 48(45.3) 63 (45.0) 35 (51.5) 73 (67.6)* ** ***
Procedural features
Thrombolysis, n (%) 16 (15.1) 19 (13.6) 7 (10.3) 14 (13.0)
Primary PTCA/CABG, n (%) 64(60.4) 96 (68.6) 45 (66.2) 61 (56.5)
Stent implantation, n (%) 73(68.9) 116 (82.9)* 52 (76.5) 68 (63.0)
LVEF, % 44.4 ± 8.1 42.8 ± 8.2 43.9 ± 8.8 43.6 ± 9.2
Peak CPK, U/L 2827 ± 1905 2988 ± 2385 2741 ± 1588 2757 ± 2393
Medications
Aspirin, n (%) 103(97.2) 138 (98.6) 66 (97.1) 104 (96.3)
ACEI/ARB, n (%) 72 (67.9) 104 (74.3) 54 (79.4) 73 (67.6)
Beta-blockers, n (%) 46(43.4) 87(62.1)* 45 (66.2)* 63(58.3)*
Statin, n (%) 46 (43.4) 65 (46.4) 39 (57.4) 45 (41.2)
Oral hypoglycemic agents, n (%) 0 (0) 0 (0) 2 (2.9) 66 (61.1)* ** ***
Insulin therapy, n (%) 0 (0) 0 (0) 0 (0) 18 (16.7)* ** ***
*; vs NGT p < 0.05 **; vs IGT p < 0.05 ***; vs NDM p < 0.05.
NGT, normal glucose tolerance; IGT, impaired glucose tolerance; NDM, newly diagnosed diabetes mellitus; PDM, previously known diabetes mellitus; IHD,
ischemic heart disease; ASO, arteriosclerosis obliterans; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting; HbA1c,
hemoglobin A1c; LDL-Cholesterol, low-density lipoprotein cholesterol; HDL-Cholesterol, high-density lipoprotein Cholesterol; MI = myocardial infarction; LVEF, left
ventricular ejection fraction; CPK, creatine phosphokinase; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.
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compared with the other groups. The NDM and PDM
groups had higher body-mass index and serum triglycer-
ide levels compared with the NGT and IGT groups. The
level of HbA1c of the NDM group was significantly
lower than that of the PDM group (5.7 ± 0.4 mg/dL vs.
8.1 ± 1.5 mg/dL, p <0.05). Only 2.9% of patients in the
NDM group were being treated by oral hypoglycemic
agents, while 61.1% and 16.7% of patients in the PDM
group were being treated by oral hypoglycemic agents
and insulin therapy, respectively. The prevalence of
NGT, IGT, NDM, and PDM was 25%, 32%, 16%, and
26%, respectively.
Of the 310 patients who were tested with 75 g OGTT,
204 patients (66%) showed post-load hyperglycemia of
≥140 mg/dL. Only 4 patients showed impaired fasting
glucose tolerance with a fasting blood glucose level of
110 mg/dL to 126 mg/dL.
Long-term MACE
Long-term MACE were observed in 120 patients. Table
2 shows the numbers of long-term MACE among study
patients. There were 40 cardiovascular events in the
PDM group, 24 events in the NDM group, 32 events in
the IGT group, and 24 events in the NGT group. The
2-year cumulative event free rates from MACE were
63.0% for the PDM group, 64.7% for the NDM group,
77.1% for the IGT group, and 77.4% for the NGT group.
Figure 2 shows Kaplan-Meier plots of study patients
with MACE during the 2-year follow-up period. The
PDM group and the NDM group showed significantly
higher event rates than non-diabetic patients and the
NDM group had a similar event rate to the PDM group.
There was no significant difference in event free rate
between the IGT group and the NGT group during the
follow-up period.
Predictors of long-term MACE
The clinical characteristics were compared between
non-PDM patients with and without MACE (Table 3).
There was no significant difference in long-term MACE
rate between non-PDM patients with and without
MACE although the 2 h post-load plasma glucose
appeared to be related to the occurrence of MACE.
Logistic analyses were carried out to examine an inde-
pendent predictive value of the 2 h post-load plasma
glucose level for long-term MACE. The adjusted vari-
ables were the 5 factors that were previously reported to
Figure 1 Study profile.
Table 2 Long-term MACE in Patients with Acute
Myocardial Infarction during 2-year Follow-up
Long-term MACE
(>30 days)
NGT IGT NDM PDM
106 140 68 108
Cardiac death, n (%) 0 0 0 4 (4)
Non-fatal acute myocardial infarction,
n (%)
0 2 (1) 2 (3) 1 (1)
Hospitalization for heart failure, n (%) 3 (3) 3 (2) 1 (1) 4 (4)
Revascularization
Target vessel revascularization, n (%) 18
(17)
20
(14)
19
(28)
25
(23)
Revascularization to de novo lesion,
n (%)
3 (3) 7 (5) 2 (3) 6 (6)
Total MACE, n (%) 24
(23)
32
(23)
24
(35)
40
(37)
MACE, major adverse cardiovascular events; NGT, normal glucose tolerance;
IGT, impaired glucose tolerance; NDM, newly diagnosed diabetes mellitus;
PDM, previously known diabetes mellitus.
Kitada et al. Cardiovascular Diabetology 2010, 9:75
http://www.cardiab.com/content/9/1/75
Page 4 of 9be related to MACE: age, left ventricular ejection frac-
tion, multi-vessel disease, use of beta-blockers, and sta-
tin use.
The ROC analysis indicated that a cut-off value of 2 h
post-load plasma glucose level ≥160 mg/dL best pre-
dicted MACE in non-PDM patients. This measure of
post-load glucose value showed a sensitivity and specifi-
city of 59% and 58%, respectively. The positive and
negative predictive values of 2 h post-load plasma glu-
cose level ≥160 mg/dL were 32% and 80%, respectively.
The odds ratio of 2 h post-load plasma glucose values
for MACE was 1.85 (95% CI: 1.07-3.21) for patients
with glucose level ≥160 mg/dL. The logistic models ana-
lyses revealed that 2 h post-load plasma glucose values
of ≥160 mg/dL was the only independent predictor of
long-term MACE after AMI (p = 0.028, OR: 1.85, 95%
CI: 1.07-3.21). Event-free survival rate was also com-
pared between patients with 2 h post-load plasma glu-
cose ≥160 mg/dL vs. <160 mg/dL, and patients with 2 h
post-load plasma glucose ≥160 mg/dL vs. PDM group.
The 2-year event-free rate of patients with 2 h post-load
plasma glucose ≥160 mg/dL was significantly higher
than that of patients with post-load plasma glucose
<160 mg/dL (67.8% vs. 80.2%, p <0.05) and was similar
to that of PDM group (62.6%, p = 0.513) (Figure 3).
Discussion
Relationship between glucometabolic status and long-
term MACE
During the 2-year follow-up, the incidence of cardiovas-
cular events after AMI was 37.0% in patients with PDM
and 35.3% in patients with NDM. Both groups had simi-
larly increased risk of long-term MACE after AMI and
significantly higher incidence of MACE compared with
non-diabetic patients including IGT patients. When
baseline characteristics were compared between the
N D Ma n dP D Mg r o u p s ,t h el e v e lo fH b A 1 co fN D M
group was significantly lower than that of PDM group
(5.7 ± 0.4 mg/dL vs. 8.1 ± 1.5 mg/dL, p <0.05). These
results indicate that patients with diabetes may have an
increased risk of cardiovascular events after AMI irre-
spective of diabetic status such as severity or disease
duration of DM. Therefore, early detection of NDM
using a 75 g OGTT after AMI may be important in the
risk assessment of cardiac events.
Several previous epidemiological studies have indi-
cated that even patients with pre-diabetic conditions,
below the diabetic threshold, are at high risk of cardio-
vascular disease [5-7]. The GAMI study and a study by
Tamita et al [13] showed that AGT including IGT and
NDM was a risk factor of increased cardiac events after
AMI [12,13]. However, it is unclear whether patients
with post-load hyperglycemia below the threshold for
DM after AMI have a risk of long-term cardiovascular
events. The Euro Heart Survey has reported that PDM
or NDM, but not IGT, has a negative influence on the
1-year outcome in patients with coronary artery disease
[16]. In the current study, we similarly demonstrated
that NDM is a factor for increased risk of cardiac events
as is PDM after AMI, but there was no significant differ-
ence for long-term MACE between IGT and NGT
patients.
Predictive value of 2 h post-load plasma glucose for long-
term MACE
We demonstrated that patients with a 2 h post-load
plasma glucose value ≥160 mg/dL, including patients
with plasma glucose value consistent with DM, had a
significantly higher risk of long-term MACE after AMI
than the patients with post-load glucose value <160 mg/
dL. Although we demonstrated NDM patients had an
increased risk of cardiac events after AMI in the present
study, we confirmed that patients with post-load hyper-
glycemia (≥160 mg/dL) had increased risk of poor long-
term outcomes after AMI. Previous investigators have
suggested several potential predictors for long-term car-
diovascular events in patients with AMI, including
impaired left ventricular function, residual ischemia, and
pharmacological therapy [17-25]. Even after adjustment
for previously proposed predictors and age, we found
that a 2 h post-load plasma glucose level ≥160 mg/dL is
another potential predictor of long-term cardiovascular
events after AMI. The cut-off points for DM on fasting
and 2 h post-load glucose values were primarily deter-
mined based on the prevalence of microvascular disease
related to hyperglycemic complications like diabetic reti-
nopathy. We may need to reconsider the thresholds
Figure 2 Kaplan-Meier curves showing event-free survival from
MACE after AMI during the 2-year follow-up among the 4
groups.
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Previously Known to have Diabetes Mellitus
Patientswith Cardiovascular Events Patients without Cardiovascular Events
(n = 80 ) (n = 234) p value
Basic characteristics
Male, n (%) 59 (73.8) 182 (78.1) 0.44
Age, year 64 ± 11 64 ± 10 0.91
Body-mass index, kg/m
2 23.5 ± 2.8 23.7 ± 2.8 0.71
Family history of IHD, n (%) 26 (32.5) 68 (29.2) 0.58
History of smoking, n (%) 58(72.5) 177 (76.0) 0.55
Clinical history
Hypertension, n (%) 45 (56.3) 144 (61.8) 0.43
Hyperlipidemia, n (%) 52 (65.0) 137 (58.8) 0.36
Heart failure, n (%) 1 (1.3) 3 (1.3) >0.99
Cerebrovascular disease, n (%) 4 (5.0) 14 (6.0) >0.99
Chronic renal failure, n (%) 2 (2.5) 10 (4.3) 0.74
ASO, n (%) 6 (7.5) 9 (3.9) 0.22
Chronic obstructive pulmonary disease, n (%) 1 (1.3) 7 (3.0) 0.69
Malignancy, n (%) 5 (6.3) 12 (5.2) 0.78
Previous procedures (PTCA/CABG), n (%) 6 (7.5) 10 (4.3) 0.25
Laboratory data at the time of admission
Fasting blood sugar, mg/dL 95 ± 9 94 ± 10 0.45
Blood sugar after 2 h, mg/dL 172 ± 51 160 ± 49 0.07
HbA1c, % 5.4 ± 0.5 5.4 ± 0.4 0.75
Total Cholesterol, mg/dL 198 ± 34 194 ± 38 0.34
Triglyceride, mg/dL 109 ± 73 107 ± 71 0.85
LDL-Cholesterol, mg/dL 134 ± 34 128 ± 34 0.18
HDL-Cholesterol, mg/dL 42 ± 9 44 ± 15 0.16
Serum creatinine, mg/dL 0.8 ± 0.2 0.8 ± 0.3 0.66
Urea acid, mg/dL 5.4 ± 1.6 5.5 ± 1.5 0.75
Characteristics of acute myocardial infarction
Systolic blood pressure on admission, mmHg 136 ± 26 138 ± 23 0.65
Heart rate on admission, bpm/m 77 ± 18 73 ± 16 0.14
Killip class≧Ⅱ, n (%) 7 (8.8) 11 (4.7) 0.26
Anterior MI, n (%) 42 (52.5) 108 (46.4) 0.37
Multi-vessel disease, n (%) 42 (52.5) 104 (44.6) 0.24
Procedural features
Thrombolysis, n (%) 12 (15.0) 30 (12.9) 0.7
Primary PTCA/CABG, n (%) 47 (58.8) 158 (67.8) 0.17
Stent implantation, n (%) 63 (78.8) 178 (76.4) 0.75
LVEF, % 42.2 ± 8.5 44.0 ± 8.2 0.11
Peak CPK, U/L 2965 ± 1836 2857 ± 2154 0.71
Medications
Aspirin, n (%) 79 (98.8) 227 (97.4) 0.68
ACEI/ARB, n (%) 59 (73.8) 171 (73.4) >0.99
Beta-blockers, n (%) 53 (66.3) 125 (53.6) 0.07
Statin, n (%) 37 (46.3) 112 (48.1) 0.8
Oral hypoglycemic agents, n (%) 1 (1.3) 1 (0.4) 0.45
IHD, ischemic heart disease; ASO, arteriosclerosis obliterans; PTCA, percutaneous transluminal coronary angioplasty; CABG, coronary artery bypass grafting; HbA1c,
hemoglobin A1c; LDL-Cholesterol, low-density lipoprotein cholesterol; HDL-Cholesterol, high-density lipoprotein Cholesterol; MI, myocardial infarction; LVEF, left
ventricular ejection fraction; CPK, creatine phosphokinase; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.
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cular disease or cardiac events after AMI.
Relationship between long-term MACE and post-load
hyperglycemia
Previous studies have shown that elevated plasma glu-
cose adversely affects endothelium-dependent vasodila-
tion, inflammatory responses, and increases oxidative
stress on the cardiovascular system [26-30]. These
hyperglycemic stresses may appear below the threshold
glucose level for DM and play an important role for
promoting cardiovascular events after AMI. Fasting glu-
cose and glycated haemoglobin provide no information
on glucose metabolism after glucose load. It is impor-
tant to use an OGTT to evaluate glucose tolerance
among patients with AMI [31,32]. Because we demon-
strated that patients with a glucose value ≥160 mg/dL
had a high risk of long-term MACE, similar to the PDM
group, early detection of post-load hyperglycemia of
≥160 mg/dL using an OGTT may be useful in the risk
management of patients with AMI. In addition, adjunc-
tive therapy for these patients may improve long-term
cardiac events after AMI. Further study is needed to
confirm this observation.
Usefulness of OGTT for patients with AMI
In the current study, 74% of the study patients showed
abnormal glucose tolerance (32% for IGT, 16% for
NDM, 26% for PDM). Recent studies have shown that
NDM and IGT are common among patients with cor-
onary artery disease including acute coronary syndrome
[8-11,33,34]. According to the European registry, when
patients with AMI, but without PDM, were challenged
with an OGTT, about 65% showed abnormal glucose
regulation [33]. We found that 74% of study patients
had abnormal glucose tolerance, which was similar to
the 65% reported previously [33].
Clinical perspectives of intervention for post-load
hyperglycemia
Although several previous studies have confirmed that
post-load hyperglycemia or impaired fasting glucose
increases cardiovascular disease morbidity and mortality
[35-37], it is still unknown whether lifestyle modification
and medication for hyperglycemia would reduce this
risk. However, in the report from the Euro Heart Survey
on Diabetes and the Heart [38], it has been noted that
lowering blood glucose using metformin may reduce the
risk of cardiovascular events among patients with DM.
According to the PROACTIVE Study [39], pioglitazone
significantly reduced the occurrence of cardiovascular
events in patients with DM who have a high risk of
macrovascular events. Recently, preliminary data have
shown that there was a pronounced decrease in cardio-
vascular events in patients with NDM prescribed glu-
cose-lowering drugs compared with those not receiving
such treatment [38]. On the other hand, it has not been
ascertained that for patients with IGT such interven-
tions also reduce the risk of cardiovascular events. The
STOP-NIDDM study [40] showed that the rate of cardi-
ovascular events was significantly reduced in the
patients with IGT who received acarbose compared with
placebo. In a further study, we have to address the issue
of whether the control of post-load hyperglycemia
would reduce the risk of recurrence of cardiovascular
events after AMI.
Study limitations
This study was a nonrandomized retrospective analysis
based on a small number of patients in a single center.
Therefore, our results may not reflect the real world
p o p u l a t i o n .S e c o n d ,w ee x c l u d e df r o mt h es t u d y1 8 8
patients (25%) who did not consent to have the 75 g
OGTT. Enrolling more patients who consent to having
t h e7 5gO G T Tm i g h tm a k et h er e s u l t sm o r ec o n v i n -
cing. In this study, we evaluated glucose tolerance of
study patients at only two time points, fasting and 2 h
post-load, using a 75 g OGTT. Estimating of post-load
hyperglycemia and parameters such as plasma insulin
level could better clarify the relationship of post-load
hyperglycemia and cardiovascular events after AMI [41].
Large randomized prospective clinical trials are needed
to support our conclusions.
Conclusions
NDM increases the risk of MACE after AMI as does
PDM. NDM and PDM patients have a similar poor
prognosis for MACE after AMI. Particularly, post-AMI
Figure 3 Kaplan-Meier curves showing event-free survival from
MACE after AMI among patients with 2 h post-load plasma
glucose ≥160 mg/dL, with 2 h post-load plasma glucose <160
mg/dL, and with previously known DM.
Kitada et al. Cardiovascular Diabetology 2010, 9:75
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Page 7 of 9patients with a 2 h post-load hyperglycemia ≥160 mg/dL
may need adjunctive therapy after AMI.
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